Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT03122223

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants (HVTN 120)

A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants

Sponsor: GlaxoSmithKline

Conditions HIV Infections

Interventions ALVAC-HIV (vCP2438) Bivalent subtype C gp120/AS01(B) Bivalent subtype C gp120/MF59 Placebo

Updated 20 times since 2017 Last updated: Mar 13, 2023 Started: Jan 16, 2018 Primary completion: Jul 30, 2020 Completion: Jul 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates HIV Infections and is currently completed. GlaxoSmithKline leads this study, which shows 20 recorded versions since 2018 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

20 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Nov 2021 — Apr 2023 [monthly]

Completed PHASE1_PHASE2
Sep 2021 — Nov 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 15 earlier versions

Feb 2021 — Sep 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE1_PHASE2
Dec 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Nov 2019 — Dec 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2018 — Nov 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2018 — Nov 2018 [monthly]

Recruiting PHASE1_PHASE2
Aug 2018 — Oct 2018 [monthly]

Recruiting PHASE1_PHASE2
Jul 2018 — Aug 2018 [monthly]

Recruiting PHASE1_PHASE2
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE1_PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2
Mar 2018 — May 2018 [monthly]

Recruiting PHASE1_PHASE2
Feb 2018 — Mar 2018 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2018 — Feb 2018 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Dec 2017 — Jan 2018 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Jun 2017 — Dec 2017 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
National Institute of Allergy and Infectious Diseases (NIAID)
Sanofi Pasteur, a Sanofi Company

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Chitungwiza, Zimbabwe , Cleveland, United States , Decatur, United States , Lusaka, Zambia , Mbeya, Tanzania , Nashville, United States , Philadelphia, United States , Rochester, United States , San Francisco, United States and 1 more location